Current state and future directions of neurochemical biomarkers for Alzheimer's disease.
SourceClinical Chemistry and Laboratory Medicine, 45, 11, (2007), pp. 1421-34
Article / Letter to editor
Display more detailsDisplay less details
Clinical Chemistry and Laboratory Medicine
SubjectDCN 1: Perception and Action; DCN 2: Functional Neurogenomics; DCN 3: Neuroinformatics; IGMD 5: Health aging / healthy living; NCEBP 11: Alzheimer Centre; NCEBP 14: Cardiovascular diseases; NCEBP 4: Quality of hospital and integrated care; UMCN 3.2: Cognitive neurosciences; UMCN 5.1: Genetic defects of metabolism
In this comprehensive review, we summarize the current state-of-the-art of neurochemical biomarkers for Alzheimer's disease. Predominantly, these biomarkers comprise cerebrospinal fluid biomarkers directly related to the pathophysiology of this disorder (such as amyloid beta protein, tau protein). We particularly pay attention to the innovations in this area that have been made in technological aspects during the past 5 years (e.g., multiplex analysis of biomarkers, proteomics), to the discovery of novel, potential biomarkers (e.g., amyloid beta oligomers, isoprostanes), and to the extension of this research towards identification of biomarkers in plasma.
Upload full text
Use your RU credentials (u/z-number and password) to log in with SURFconext to upload a file for processing by the repository team.